FDA can't regulate compounded Rxs

Share this article:
In a bench decision, Texas Western District federal judge Robert Junell ruled in May that pharmacy-compounded drugs are not new drugs subject to FDA regulation, as the agency has unsuccessfully asserted in various courts for over a decade. In 2002, the FDA lost in an advertising-related compounding case in the Supreme Court.

Junell granted summary judgment in part to the plaintiffs Medical Center Pharmacy, et al. against the government, leaving two issues to be decided: the scope of the FDA's authority to inspect pharmacies' records, and pharmacies' ability to compound using bulk active ingredients for non-food-animal drugs

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.